We also identified FMS-related receptor tyrosine kinase 1 (FLT1) as a potential target for repurposing, which previously has not been evaluated for B-ALL in clinical trials. This evidence concerns the gene FLT1 and precursor B-cell acute lymphoblastic leukemia.